MariMed Past Earnings Performance
Past criteria checks 0/6
MariMed has been growing earnings at an average annual rate of 43.7%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 35.2% per year.
Key information
43.7%
Earnings growth rate
47.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 35.2% |
| Return on equity | -18.0% |
| Net Margin | -10.8% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How MariMed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 149 | -16 | 51 | 0 |
| 30 Sep 23 | 146 | -1 | 49 | 0 |
| 30 Jun 23 | 141 | 6 | 45 | 0 |
| 31 Mar 23 | 137 | 9 | 43 | 0 |
| 31 Dec 22 | 134 | 13 | 43 | 0 |
| 30 Sep 22 | 129 | 2 | 44 | 0 |
| 30 Jun 22 | 129 | 2 | 46 | 0 |
| 31 Mar 22 | 128 | 7 | 43 | 0 |
| 31 Dec 21 | 121 | 7 | 39 | 0 |
| 30 Sep 21 | 111 | 18 | 29 | 0 |
| 30 Jun 21 | 91 | 17 | 22 | 0 |
| 31 Mar 21 | 68 | 9 | 19 | 0 |
| 31 Dec 20 | 51 | 2 | 17 | 0 |
| 30 Sep 20 | 36 | -80 | 50 | 0 |
| 30 Jun 20 | 33 | -89 | 48 | 0 |
| 31 Mar 20 | 50 | -84 | 48 | 0 |
| 31 Dec 19 | 46 | -81 | 46 | 0 |
| 30 Sep 19 | 44 | -10 | 16 | 0 |
| 30 Jun 19 | 36 | -7 | 15 | 0 |
| 31 Mar 19 | 13 | -12 | 13 | 0 |
| 31 Dec 18 | 12 | -14 | 12 | 0 |
| 30 Sep 18 | 10 | -7 | 7 | 0 |
| 30 Jun 18 | 8 | -4 | 6 | 0 |
| 31 Mar 18 | 7 | -3 | 5 | 0 |
| 31 Dec 17 | 6 | -1 | 4 | 0 |
| 30 Sep 17 | 6 | 0 | 3 | 0 |
| 30 Jun 17 | 5 | 0 | 2 | 0 |
| 31 Mar 17 | 4 | 0 | 2 | 0 |
| 31 Dec 16 | 4 | 0 | 1 | 0 |
Quality Earnings: MRMD is currently unprofitable.
Growing Profit Margin: MRMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRMD is unprofitable, but has reduced losses over the past 5 years at a rate of 43.7% per year.
Accelerating Growth: Unable to compare MRMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: MRMD has a negative Return on Equity (-18%), as it is currently unprofitable.